TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
TEVA$42.40-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(U.S. dollars in millions)
| Three months ended | ||
|---|---|---|
| March 31, | ||
| 2025 | 2024 | |
| Operating activities: | ||
| Net income (loss) | $220 | (419) |
| Adjustments to reconcile net income (loss) to net cash provided by operations: | ||
| Depreciation and amortization | 244 | 272 |
| Impairment of long-lived assets and assets held for sale | 77 | 679 |
| Net change in operating assets and liabilities | (700) | (497) |
| Deferred income taxes – net and uncertain tax positions | 28 | (189) |
| Stock-based compensation | 34 | 28 |
| Other items | (8) | 2 |
| Net cash provided by (used in) operating activities | (105) | (124) |
| Investing activities: | ||
| Beneficial interest collected in exchange for securitized trade receivables | 322 | 295 |
| Purchases of property, plant and equipment and intangible assets | (127) | (124) |
| Proceeds from sale of business and long-lived assets, net | 17 | — |
| Acquisition of businesses, net of cash acquired | — | (15) |
| Purchases of investments and other assets | (11) | (12) |
| Net cash provided by (used in) investing activities | 201 | 144 |
| Financing activities: | ||
| Repayment of senior notes and loans and other long-term liabilities | (1,368) | — |
| Purchase of shares from redeemable and non-redeemable non-controlling interests | (38) | (64) |
| Dividends paid to redeemable and non-redeemable non-controlling interests | (340) | (78) |
| Other financing activities | 3 | (9) |
| Net cash provided by (used in) financing activities | (1,744) | (151) |
| Translation adjustment on cash and cash equivalents | 45 | (104) |
| Net change in cash, cash equivalents and restricted cash | (1,603) | (236) |
| Balance of cash, cash equivalents at beginning of period | 3,300 | 3,227 |
| Balance of cash, cash equivalents at end of period | $1,697 | 2,991 |
| Non-cash financing and investing activities: | ||
| Beneficial interest obtained in exchange for securitized accounts receivables | $311 | 312 |
Amounts may not add up due to rounding
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.